BMS-986165 Tablet

DRUG3 trials

Sponsors

Bristol-Myers Squibb, InventisBio Co., Ltd

Conditions

Arthritic PsoriasisInflammatory Bowel DiseasesLupusPlaque PsoriasisPsoriasisSystemic Lupus Erythematosus

Phase 1

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

CompletedNCT03254784

Bristol-Myers SquibbArthritic Psoriasis, Inflammatory Bowel Diseases, Psoriasis +1

Start: 2017-09-13End: 2017-11-15Updated: 2020-02-25

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

CompletedNCT04065932

Bristol-Myers SquibbLupus

Start: 2019-08-22End: 2019-12-10Updated: 2021-01-06

Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

RecruitingNCT07326813

InventisBio Co., LtdPlaque Psoriasis

Start: 2026-01-12End: 2027-12-03Target: 477Updated: 2026-04-29